Zydus Lifesciences Q1 Results FY26: Q1 PAT Rises 3.30% to ₹1,466.80 Crore; Revenue Up 5.90% YoY

Zydus Lifesciences Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Zydus Lifesciences Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Zydus Lifesciences Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Zydus Lifesciences clocked Q1 FY26 consolidated revenue of ₹6,573.70 crores vs ₹6,207.50 crores. 
• On the profit front, Zydus Lifesciences earned a consolidated PAT of ₹1,466.80 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹1,419.90 crore. 
• Consolidated PAT rose for the first quarter of FY26, was 3.30% YoY, and revenue increased by 5.90% YoY. 
• As per the standalone figures, the quarterly PAT of Zydus Lifesciences has decreased by 77.38%, and revenue has decreased by 37.78% YoY.

Zydus Lifesciences Share Price Performance

On the opening bell of 12th August 2025, the shares of Zydus Lifesciences opened at ₹955.95 per share. However, the initial gains are wiped out as of now, and Zydus Lifesciences shares are trading at ₹955.00 per share, lower than their opening price. 

Considering the long-term performance, Zydus Lifesciences shares have yielded close to -23.62% returns in the past 1 year, and 5-year returns stand at 141.50%. Over the maximum timeframe, the Zydus Lifesciences share provided 11,867.42% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Zydus Lifesciences shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your research before investing in shares and other securities.

Recent Articles

HBL Engineering Q1 Results FY26: Q1 PAT Rises 78.87% to ₹143.27 Crore; Revenue Up 15.70% YoY

Fine Organic Q1 Results FY26: Q1 PAT Rose 7.04% to ₹117.10 Crore; Revenue Up 7.04% YoY

Eureka Forbes Q1 Results FY26: Q1 PAT Rises 20.32% to ₹38.68 Crore; Revenue Up 9.85% YoY

JM Financial Q1 Results FY26: Q1 PAT Rose 165.85% to ₹453.81 Crore; Revenue Up 3.18% YoY

IPCA Laboratories Q1 Results FY26: Q1 PAT Rises 21.31% to ₹233.21 Crore; Revenue Up 10.33% YoY